SAN DIEGO, Aug. 11, 2015 /PRNewswire-USNewswire/ -- The Pan Am Cancer Treatment Center, an institution dedicated to providing cutting-edge immunotherapies to cancer patients in an accelerated manner, announced today availability of ImmunoMax to advanced cancer patients that meet inclusion criteria. The Pan Am Cancer Treatment Center focuses on a variety of solid tumors including lung cancer, colon cancer, prostate cancer, breast cancer, kidney cancer, glioblastoma and melanoma.
ImmunoMax is a pharmaceutical grade polysaccharide of plant origin that has been demonstrated to stimulate natural killer cells (1). ImmunoMax has been on the market in Russia for 13 years for treatment of viral and bacterial infections, with reports demonstrating reduction of PSA in prostate cancer patients (2).
"It is well known that many cancer patients have suppressed natural killer cell activity as compared to healthy controls, studies have demonstrated that patients with low natural killer cell activity have a poorer prognosis as compared to patients with higher natural killer cell activity (3-5)," said Dr. Javier Lopez, Chief Executive Officer of the Pan Am Cancer Treatment Center. "Efficacy of numerous cancer therapies offered by oncologists such as Herceptin (6,7), Rituximab (8), and Cetuximab (9), has been shown to depend on activity of the patient's natural killer cells. It is conceivable that utilization of ImmunoMax by itself, or in combination with existing therapies may be of benefit to cancer patients."
In 2015, a peer-reviewed paper authored by scientists at the University of California Irvine, the Institute for Molecular Medicine, and the Gamaley Research Institute of the Russian Ministry of Health demonstrated that ImmunoMax activates not only natural killer cells but also dendritic cells. Additionally, the study demonstrated profound inhibition of breast cancer growth and metastasis in a higher aggressive animal model (10).
"In an age where the promise of cancer immunotherapy has the medical community electrified with positive results from trials using checkpoint inhibitors and CAR-T cells, it is important to remember that the innate immune system is critical both to initiation of antitumor immunity, as well as maintenance of the immune response and establishment of immunological memory," said Dr. Julio Selva Pallares, Medical Director of the Pan Am Cancer Treatment Center. "We are proud to begin offering, to patients that fit the criteria, access to ImmunoMax, which in our opinion is a highly promising immune stimulatory therapeutic."
"In my opinion, after 13 years of using ImmunoMax as an immune stimulant in Russia and CIS countries as an approved pharmaceutical drug, I believe that we are adding a potent weapon in the arsenal of the Pan Am Cancer Treatment Center," said Dr. Ravshan Ataullakhanov, MD, Ph.D, DSc, inventor of ImmunoMax and Professor of Immunology at the Institute of Immunology and Lomonosov Moscow State University.
About Pan Am Cancer Treatment Center
The Pan Am Cancer Treatment Centers offer access to cutting edge cancer immunotherapies outside of clinical trials. Today safety of many immunotherapies has already been demonstrated, but the majority are currently in efficacy finding Phase III clinical trials. Unfortunately, in these trials, some patients are placed into the placebo group. The Pan Am Cancer Treatment Centers offer access to cellular, small molecule, and protein therapeutics through accelerated means, in addition to novel combination immunotherapies.
Patient Services Coordinator
Phone: (619) 735-9581
(2). Ataullakhanov et al. ImmunomaxR therapy to obtain relief in papilloma virus infections, prostatitis, and prostate carcinoma. J Mens Health. 2010;7:396–405.
(3). Lowdell et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol. 2002 Jun;117(4):821-7. http://www.ncbi.nlm.nih.gov/pubmed/12060116/
(4). Osada et al. NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. Cancer Immunol Immunother. 2006 Sep;55(9):1122-31. http://www.ncbi.nlm.nih.gov/pubmed/16273350
(5). Kondo et al. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. http://www.ncbi.nlm.nih.gov/pubmed/12900537
(6). Beano et al. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med. 2008 May 16;6:25. http://www.ncbi.nlm.nih.gov/pubmed/18485193
(7). Arnould et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006 Jan 30;94(2):259-67. http://www.ncbi.nlm.nih.gov/pubmed/16404427/
(8). Rudnicka et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. 2013 Jun 6;121(23):4694-702. http://www.ncbi.nlm.nih.gov/pubmed/23613524
(9). Marechal et al. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer. 2010 Jun 30;10:340. http://www.ncbi.nlm.nih.gov/pubmed/20591136
(10). Ghochikyan et al. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, ImmunoMax®, as a therapeutic strategy for metastatic breast cancer. J Transl Med. 2014 Nov 29;12:322. http://www.ncbi.nlm.nih.gov/pubmed/25432242
SOURCE Pan Am Cancer Treatment Center